LDS Hospital
Salt Lake City, Utah, United States
NCT Number: NCT00231426
The ASSURE Study will evaluate shock conversion performance when programming the first shock of an implantable cardioverter-defibrillation (ICD) is based on an implant test consisting of either 1) a single induction of ventricular fibrillation (VF) and subsequent demonstration conversion success at 14 J or 2) an upper limit of vulnerability (ULV) test at 14 J.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Salt Lake City, Utah, United States
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Boston Scientific Corporation
Industry
Arrhythmia Single Shock DFT Versus ULV: Risk Reduction Evaluation With ICDs Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04863664
Arrhythmias, Cardiac, Cardiac Conduction System Disease
Huntsville, Alabama, United States
View Trial DetailsNCT00170274
Arrhythmias, Cardiac, Cardiac Conduction System Disease
Bad Segeberg, Germany
View Trial DetailsNCT01526629
Arrhythmias, Cardiac, Cardiac Conduction System Disease
Montfermeil, France
View Trial DetailsNCT05621187
Arrhythmias, Cardiac, Cardiac Conduction System Disease
New Lambton Heights, New South Wales, Australia
View Trial Details